Encouraging Results from the TheraPb Phase 1b Trial
In a significant advancement for cancer treatment, AdvanCell has unveiled promising findings for its investigational drug, 212Pb-ADVC001, during the Phase 1b dose escalation of the TheraPb clinical trial. Presented at the European Society for Medical Oncology (ESMO) 2025 congress, these results highlight the drug’s potential as a radioligand therapy for patients suffering from metastatic castration-resistant prostate cancer (mCRPC). The trial demonstrated a favorable safety profile without any dose-limiting toxicities or serious treatment-related adverse events, marking a pivotal moment for therapeutic options in this challenging field.
Impressive Safety and Efficacy Profile
The data derived from the trial, which enrolled 22 patients with mCRPC, indicated that 80% of participants experienced a biochemical response (PSA50) at doses equal to or greater than 160 MBq. Furthermore, the study reported a remarkable 100% objective response rate (ORR) in patients with measurable lesions, including two cases of complete response. Dr. Anna Karmann, Chief Medical Officer of AdvanCell, expressed optimism about the trial’s outcomes, stating that the results could significantly influence future treatment landscapes for prostate cancer. She acknowledged the vital contributions of the clinical teams and patients that made this milestone possible.
Future Directions and Phase 2 Expansion
The encouraging findings have laid the groundwork for a Phase 2 expansion, which will further evaluate doses of 160 MBq and 200 MBq of 212Pb-ADVC001. This next phase will adopt a randomized multi-dose-response design to refine dosing strategies and optimize patient outcomes across different indications, including both chemo-naïve and post-177Lu-PSMA mCRPC patients, as well as hormone-sensitive prostate cancer (mHSPC). Dr. Aaron Hansen, the principal investigator at Princess Alexandra Hospital, highlighted the clinical advantages of this therapy, emphasizing its ease of administration in outpatient settings and its potential to reduce tumor volume and prostate-specific antigen (PSA) levels significantly.
Significance of 212Pb-ADVC001 in Cancer Treatment
The development of 212Pb-ADVC001 marks a critical step in the evolution of targeted therapies for prostate cancer. As a proprietary PSMA-targeting radioligand, it utilizes Lead-212 as an alpha-emitting payload to deliver localized radiation to cancer cells while minimizing collateral damage to surrounding healthy tissues. The promising results from this trial set a new reference point for future studies and may challenge the existing treatment paradigms for prostate cancer.
As research and development continue, AdvanCell aims to harness its innovative technology to improve patient outcomes in cancer treatment globally, positioning itself as a front-runner in the field of targeted alpha therapies. Further updates and detailed findings can be accessed on the AdvanCell website, reflecting the company’s commitment to transparency and patient engagement in cancer research.
Related
